Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Annexon Biosciences (ANNX) and VolitionRX (VNRX)

Tipranks - Tipranks - Fri Apr 3, 9:54AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiol Therapeutics (CRDL), Annexon Biosciences (ANNX) and VolitionRX (VNRX) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Cardiol Therapeutics (CRDL)

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Cardiol Therapeutics, with a price target of $9.00. The company’s shares closed last Thursday at $1.44.

According to TipRanks.com, Folkes is a 1-star analyst with an average return of -1.7% and a 35.4% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Rani Therapeutics Holdings, and Connect Biopharma Holdings. ;'>

Cardiol Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.

See today’s best-performing stocks on TipRanks >>

Annexon Biosciences (ANNX)

In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Annexon Biosciences, with a price target of $14.00. The company’s shares closed last Thursday at $5.54.

According to TipRanks.com, Ghosh is a 5-star analyst with an average return of 54.8% and a 62.3% success rate. Ghosh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Maze Therapeutics, Inc., and ACADIA Pharmaceuticals. ;'>

Annexon Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $15.40, which is a 193.1% upside from current levels. In a report issued on March 18, J.P. Morgan also maintained a Buy rating on the stock.

VolitionRX (VNRX)

JonesTrading analyst Justin Walsh reiterated a Buy rating on VolitionRX today and set a price target of $3.00. The company’s shares closed last Thursday at $0.18.

According to TipRanks.com, Walsh is a 5-star analyst with an average return of 19.2% and a 35.6% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, NeuroOne Medical Technologies, and Bioline RX Ltd Sponsored ADR. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VolitionRX with a $3.00 average price target.

Read More on CRDL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).